PRIME: eligibility requests and outcomes
Submitted by Anonymous (not verified) on 6 October 2026 - 17:00
PRIME: eligibility requests and outcomes
Recommendations on eligibility to PRIME scheme adopted at the CHMP meetings of 2026
Submitted by Anonymous (not verified) on 6 October 2026 - 17:00
Recommendations on eligibility to PRIME scheme adopted at the CHMP meetings of 2026
PRIME: priority medicines
Submitted by Anonymous (not verified) on 6 October 2026 - 17:00
PRIME: priority medicines
List of medicines currently in PRIME scheme
Submitted by Anonymous (not verified) on 6 October 2026 - 16:50
List of medicines currently in PRIME scheme
Human medicines European public assessment report (EPAR): Kinzalmono (previously Telmisartan Boehringer Ingelheim Pharma KG), telmisartan, Date of authorisation: 16/12/1998, Revision: 32, Status: Withdrawn
Submitted by Anonymous (not verified) on 6 October 2026 - 16:25
Human medicines European public assessment report (EPAR): Kinzalmono (previously Telmisartan Boehringer Ingelheim Pharma KG), telmisartan, Date of authorisation: 16/12/1998, Revision: 32, Status: Withdrawn
How to submit information on authorised and investigational medicines
Submitted by Anonymous (not verified) on 6 October 2026 - 16:08
How to submit information on authorised and investigational medicines
Reporting requirements for marketing-authorisation holders
Submitted by Anonymous (not verified) on 6 October 2026 - 15:56
Reporting requirements for marketing-authorisation holders
PRAC rules of procedure
Submitted by Anonymous (not verified) on 6 October 2026 - 15:46
PRAC rules of procedure
Human medicines European public assessment report (EPAR): Steqeyma, ustekinumab, Date of authorisation: 22/08/2024, Revision: 10, Status: Authorised
Submitted by Anonymous (not verified) on 6 October 2026 - 15:42
Human medicines European public assessment report (EPAR): Steqeyma, ustekinumab, Date of authorisation: 22/08/2024, Revision: 10, Status: Authorised
Concept paper on the guideline revision on good pharmacogenomic practice
Submitted by Anonymous (not verified) on 6 October 2026 - 15:40
Concept paper on the guideline revision on good pharmacogenomic practice